IN A RECENT ISSUE of the American Journal of PhysiologyGastrointestinal and Liver Physiology, Schierwagen et al. (8) reviewed the outcomes of statins on liver and cardiovascular disease (CVD) (8) . A few comments might be of interest.
In 2010, our post hoc analysis of the GREek Atorvastatin and Coronary heart-disease Evaluation (GREACE) study (n ϭ 1,600) (3) showed that atorvastatin (average dose, 24 mg/day) for 3 yr in patients with coronary heart disease (CHD) halved CVD events in a subgroup of patients with likely nonalcoholic fatty liver disease, i.e., NAFLD, the most common liver disease (4) . Three years later, the secondary prevention Initiating Dialysis Early and Late (IDEAL) study (n ϭ 8,863) that included participants with high alanine transaminase (ALT) levels confirmed our finding for the beneficial effect both on NAFLD and CVD with high-dose atorvastatin (80 mg/day) compared with simvastatin (20 mg/day) (9). This was also the case with the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) (n ϭ 1,123)], a primary prevention study, using atorvastatin (average dose, 30 mg/day) (2). These three studies are limited by being post hoc analyses and by the absence of histology, the gold standard for the diagnosis of NAFLD/nonalcoholic steatohepatitis (NASH).
A study with biopsy-proven NASH (n ϭ 20) showed that 10 mg/day rosuvastatin eliminated histologically NASH in the repeat biopsy a year later in 19 or 20 patients (6) . Another study (n ϭ 346) with biopsy-proven NAFLD reported that statins ameliorate NAFLD/NASH (7) . There is also a study reporting benefits after administration of pitavastatin in a specific patient group (5). Other studies supporting a benefit were mentioned by Schierwagen et al. (1) .
Overall, the beneficial effect of statins on NAFLD/NASH may be statin dose related; some statins may be more effective (e.g., atorvastatin and rosuvastatin); and in addition to improved liver pathology, the high CVD event rate in these patients at high risk may decrease substantially (3). These factors need to be established/refuted by appropriately designed trials to help treatment choices for those with NAFLD/ NASH. These are highly prevalent and harmful diseases where more patients will die from a vascular death than from a hepatic death (3) . Some of these concepts are considered in a recent expert panel statement (1) . 
